THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 18 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $984,000 | -7.3% | 1,039,000 | 0.0% | 0.06% | -11.3% |
| Q1 2021 | $1,062,000 | +8.3% | 1,039,000 | 0.0% | 0.06% | +3.3% |
| Q4 2020 | $981,000 | +6.2% | 1,039,000 | 0.0% | 0.06% | -15.5% |
| Q3 2020 | $924,000 | -8.2% | 1,039,000 | 0.0% | 0.07% | -17.4% |
| Q2 2020 | $1,007,000 | -0.7% | 1,039,000 | 0.0% | 0.09% | -47.2% |
| Q1 2020 | $1,014,000 | -81.0% | 1,039,000 | -79.8% | 0.16% | -86.7% |
| Q4 2019 | $5,342,000 | +12.2% | 5,149,000 | 0.0% | 1.23% | +2.1% |
| Q3 2019 | $4,762,000 | +6.4% | 5,149,000 | 0.0% | 1.20% | +3.0% |
| Q2 2019 | $4,476,000 | -10.7% | 5,149,000 | 0.0% | 1.17% | -20.9% |
| Q1 2019 | $5,015,000 | -19.5% | 5,149,000 | -14.9% | 1.47% | -31.3% |
| Q4 2018 | $6,232,000 | -42.8% | 6,049,000 | -34.0% | 2.15% | -17.1% |
| Q3 2018 | $10,888,000 | +20.4% | 9,166,000 | 0.0% | 2.59% | +166.9% |
| Q2 2018 | $9,044,000 | -20.2% | 9,166,000 | -17.9% | 0.97% | +16.9% |
| Q1 2018 | $11,332,000 | -7.4% | 11,166,000 | 0.0% | 0.83% | -16.8% |
| Q4 2017 | $12,243,000 | – | 11,166,000 | – | 1.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|